The key August 2026 acne development was permission to test denifanstat in Phase 3—not approval of a new treatment. The more immediate change for patients was expanded over-the-counter access to a combined adapalene and benzoyl peroxide product. These developments affect different decisions. One changes what people can buy without a prescription; the other may shape future care if larger trials confirm its benefits and safety.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What happened with denifanstat?
- Which treatment became available without a prescription?
- Where does Winlevi fit?
- What changed for isotretinoin patients?
- Which findings still need caution?
What happened with denifanstat?
On August 13, Sagimet Biosciences reported that the FDA had allowed Phase 3 testing of denifanstat to proceed. Denifanstat is an investigational oral drug that inhibits FASN, meaning it remains under study and cannot yet be treated as an approved acne option. Sagimet plans to enroll about 800 U.S.
patients aged 12 or older with moderate-to-severe acne. Participants will receive denifanstat or placebo for 12 weeks, followed by 40 weeks of follow-up for eligible participants, according to Sagimet's study announcement. The larger trial matters because it should provide stronger evidence about effectiveness and safety. Until results are available and regulators review them, any assumptions about denifanstat's eventual availability are premature.
Which treatment became available without a prescription?
The FDA approved Differin Epiduo for over-the-counter use in people aged 12 and older in May 2026. The once-daily product combines adapalene 0.1% with benzoyl peroxide 2.5% and previously required a prescription. Galderma said its rollout at major U.S. retailers would begin during summer 2026.
The company also reported inflammatory-lesion reductions of up to 70.3% after 12 weeks in cited trials, but that figure comes from the manufacturer rather than a new independent study. The approval and launch details appear in Galderma's FDA approval announcement. For readers comparing headlines, this is the change that can affect treatment access now. It does not expand the labeled age group below 12, and it should not be confused with the still-investigational denifanstat program.
Where does Winlevi fit?
The European Commission authorized topical clascoterone, sold as Winlevi, across the European Union in October 2025. It treats acne in adults and facial acne in adolescents aged 12 to 17 by targeting androgen receptors, giving patients a mechanism different from established options. In two pivotal facial-acne studies, 19.5% of Winlevi-treated patients were clear or almost clear at 12 weeks, compared with 7.7% receiving placebo.
The European Medicines Agency's Winlevi assessment also limits adolescent use to the face and includes risk measures for theoretical systemic hormonal effects and pregnancy risk. The regional distinction matters: an EU authorization does not describe U.S. access. Adolescents and people who could become pregnant should pay particular attention to the authorized use and risk information rather than treating Winlevi as an unrestricted topical product.
What changed for isotretinoin patients?
The FDA postponed planned iPLEDGE REMS changes from August 8 to November 15, 2026. Existing requirements therefore remain in effect until the delayed changes begin. Under the future framework, a prescriber may permit at-home pregnancy testing during and after isotretinoin treatment.
Testing before treatment starts would not qualify for that option, as explained in the FDA's iPLEDGE update. Patients should not assume the anticipated rules already apply. The practical step is to confirm current testing instructions with the prescriber managing iPLEDGE, especially around the November 15 transition.
Which findings still need caution?
A 2026 randomized split-face study compared two Nd:YAG laser settings in 20 adults. The Q-switched 1064-nm treatment reduced acne-severity scores by 50%, compared with 32% for the long-pulsed treatment. The result is preliminary because every participant also took daily azithromycin and the study was small.
It supports further investigation of laser treatment as an adjunct, not the conclusion that laser can replace standard therapy. Separately, EuroGuiDerm's 2025 update found that two observational studies supported the safety of standard benzoyl peroxide acne use while calling for more research. Broad concern about the ingredient is not, by itself, evidence to stop a prescribed or properly labeled treatment.